AL

Theradiag SAPAR Theradiag

Последний отчетный период 30 июня, 2020

Обновлено —

Последняя цена

Капитализация млрд. $

0.014

Micro

Биржа

XPAR - Euronext Paris

Анализ акций ALTER.PA

AL

Нет оценки

Количественный анализ Eyestock не покрывает акции Theradiag SA.

Капитализация млрд. $

0.014

Дивидендная доходность

Оборот

13.013 млрд

Сайт компании

http://www.theradiag.com

Theradiag SA engages in the distribution, development and manufacturing of in vitro diagnostic and theranostics tests. The company is headquartered in Croissy-Beaubourg, Ile-De-France. The company went IPO on 2012-12-11. The firm develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. TheraDiags product offering consists of tests using a range of techniques (Elisa, rapid tests, immunofluorescence, Dot, immunochemical tests, molecular biology, etc.) as well as a range of automatic devices and solutions for high-speed diagnostics based on Luminexs Multiplex technology. The company has also developed a range of theranostic diagnostics commercialized under the Lisa-Tracker brand which provide monitoring of patients treated by anti-TNF monoclonal antibodies. TheraDiag is active in more than 30 countries, as an independent distributor.

Смотреть Секцию: Рейтинг